SEC Comment Letter 0000000000-23-004626 to Cyteir Therapeutics, Inc. (CIK 0001662244)
Cyteir Therapeutics, Inc. (CIK 0001662244)
Date: May 4, 2023 · CIK: 0001662244 · Accession: 0000000000-23-004626
AI Filing Summary & Sentiment
File numbers found in text: 001-40499
Letter
United States securities and exchange commission logo May 4, 2023 David Gaiero Chief Financial Officer and Treasurer Cyteir Therapeutics, Inc. 128 Spring Street, Building A, Suite 510 Lexington, Massachusetts, 02421 Re:Cyteir Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 23, 2023 File No. 001-40499 Dear David Gaiero: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 4, 2023
David Gaiero
Chief Financial Officer and Treasurer
Cyteir Therapeutics, Inc.
128 Spring Street, Building A, Suite 510
Lexington, Massachusetts, 02421
Re:Cyteir Therapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed March 23, 2023
File No. 001-40499
Dear David Gaiero:
We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences